- ISIN
- US86150R1077
- CUSIP
- 86150R107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 19, 2019
Highlights
- Market Cap
- $1.86B
- Enterprise Value
- $1.70B
- EPS (TTM)
- -$2.85
- Total Revenue (TTM)
- $32.08M
- Gross Profit (TTM)
- $23.81M
- EBITDA (TTM)
- -$179.29M
- Year Range
- $10.90 - $40.22
- Target Price
- $43.86
- ROA (TTM)
- -38.30%
- ROE (TTM)
- -42.99%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
STOK Performance Chart
Stoke Therapeutics, Inc. (STOK) is down 7.2% since the beginning of the year. At $29 per share, STOK is trading 26.8% below its 52-week high of $40. Investors who bought $1,000 worth of STOK shares 5 years ago would now be looking at an investment worth $790.
Loading charts...
Returns By Period
Stoke Therapeutics, Inc. (STOK) has returned -7.18% so far this year and 170.28% over the past 12 months.
Stoke Therapeutics, Inc.
- 1D
- 2.72%
- 1M
- -13.81%
- YTD
- -7.18%
- 6M
- -4.84%
- 1Y
- 170.28%
- 3Y*
- 34.27%
- 5Y*
- -4.61%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
STOK Monthly Returns History
Based on dividend-adjusted daily data since Jun 19, 2019, STOK's average daily return is +0.13%, while the average monthly return is +2.57%. At this rate, an investment would double in approximately 2.3 years.
Historically, 47% of months were positive and 53% were negative. The best month was Mar 2024 with a return of +74.4%, while the worst month was Nov 2022 at -49.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, STOK closed higher 50% of trading days. The best single day was Mar 26, 2024 with a return of +58.3%, while the worst single day was Jul 25, 2023 at -32.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.41% | 20.01% | -10.57% | 0.49% | -5.53% | -4.69% | -7.18% | ||||||
| 2025 | 4.08% | -31.62% | -15.29% | 46.77% | -2.25% | 18.97% | 13.22% | 53.77% | 18.93% | 27.83% | 2.90% | 2.69% | 187.76% |
| 2024 | -7.98% | 59.92% | 74.42% | -18.30% | 32.55% | -7.59% | 10.81% | -2.81% | -15.53% | 0.57% | -2.02% | -8.92% | 109.70% |
| 2023 | 7.91% | -10.74% | -6.30% | 6.72% | 25.98% | -5.09% | -37.54% | -15.36% | -29.89% | -3.30% | -0.52% | 38.79% | -43.01% |
| 2022 | -21.01% | 2.90% | 7.95% | -31.40% | -16.14% | 9.08% | 11.96% | 1.83% | -14.74% | 15.65% | -49.23% | 22.41% | -61.53% |
| 2021 | -1.37% | -1.95% | -35.15% | -16.84% | 22.79% | -15.13% | -14.94% | -8.56% | -2.83% | -10.26% | 9.07% | -3.65% | -61.26% |
Benchmark Metrics
Stoke Therapeutics, Inc. has an annualized alpha of 12.66%, beta of 1.38, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since June 20, 2019.
- This stock participated in 86.59% of S&P 500 Index downside but only 47.24% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.66%
- Beta
- 1.38
- R²
- 0.12
- Upside Capture
- 47.24%
- Downside Capture
- 86.59%
Return for Risk
Risk / Return Rank
STOK ranks 91 for risk / return — in the top 91% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Stoke Therapeutics, Inc. (STOK) and compare them to S&P 500 Index.
| STOK | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.42 | ||
| Sortino ratioReturn per unit of downside risk | +0.21 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.41 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 4.61 | 2.93 | +1.68 |
| Martin ratioReturn relative to average drawdown | 14.14 | 13.52 | +0.62 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Stoke Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Stoke Therapeutics, Inc. was 95.17%, occurring on Oct 27, 2023. The portfolio has not yet recovered.
The current Stoke Therapeutics, Inc. drawdown is 57.80%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -95.17%Oct 2023 | 2y 9mo | — | 5y 4moJan 2021 - now |
COVID crash2020 | -55.46%Mar 2020 | 6mo 14d | 6mo 25d | 1y 1moSep 2019 - Oct 2020 |
2019 bear market2019 | -21.15%Jul 2019 | 21d | 22d | 1mo 13dJul 2019 - Aug 2019 |
2020 correction2020 | -12.41%Nov 2020 | 8d | 5d | 13dNov 2020 - Nov 2020 |
2020 correction2020 | -11.65%Dec 2020 | 1d | 12d | 13dDec 2020 - Dec 2020 |
Drawdown Indicators
| STOK | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.17% | -56.78% | -38.39% |
Max Drawdown (1Y)Largest decline over 1 year | -37.16% | -9.10% | -28.06% |
Max Drawdown (3Y)Largest decline over 3 years | -75.62% | -18.90% | -56.72% |
Max Drawdown (5Y)Largest decline over 5 years | -91.80% | -25.43% | -66.37% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -57.80% | -0.74% | -57.06% |
Average DrawdownAverage peak-to-trough decline | -62.31% | -10.72% | -51.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.09% | 1.97% | +10.12% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Stoke Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Stoke Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for STOK relative to other companies in the Biotechnology industry. Currently, STOK has a P/S ratio of 54.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for STOK in comparison with other companies in the Biotechnology industry. Currently, STOK has a P/B value of 4.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with STOK
Add Stoke Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with STOK